CD8A and neoplasm: Although it has been shown that PD-L1, tumor mutation burden (TMB), and CD8+ TILs are all significantly higher in patients with resistance to EGFR-tyrosine kinase inhibitor (TKI) therapy (53, 54), this elevation does not seem to translate into a benefit in immune checkpoint blockade (ICB) treatment (55–58).